BZL Biotech

BZL Biotech is a clinical-stage biotechnology company focused on the development of targeted therapies for prostate cancer. The company's core technology centers on the J591 monoclonal antibody, which specifically targets the extracellular domain of Prostate-Specific Membrane Antigen (PSMA). BZL Biotech is advancing a pipeline of PSMA-targeted agents, including radiopharmaceuticals and antibody-drug conjugates, designed to deliver therapeutic payloads directly to malignant prostate cells. Their lead programs have demonstrated potential in treating metastatic castration-resistant prostate cancer by minimizing off-target effects while maximizing anti-tumor activity.